drugset
drugset / Trial / NCT02125981

The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

NCT02125981 ↗

Phase 3 Completed 160 enrolled Seoul National University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.

Timeline

Start
2014-09-01
Primary completion
2022-10-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Limaprost Small molecule 166.67 ug Oral

Indications

spinal cord disorder